TY - JOUR
AU1 - Tuuminen, Raimo
AU2 - Jouppila, Annukka
AU3 - Salvail, Dan
AU4 - Laurent, Charles-E.
AU5 - Benoit, Marie-Claude
AU6 - Syrjälä, Simo
AU7 - Helin, Heikki
AU8 - Lemström, Karl
AU9 - Lassila, Riitta
AB - Clin Exp Nephrol (2017) 21:436–445 DOI 10.1007/s10157-016-1308-2 O R I G IN AL ARTI CL E Dual antiplatelet and anticoagulant APAC prevents experimental ischemia–reperfusion-induced acute kidney injury 1,2 3 4 4 • • • • Raimo Tuuminen Annukka Jouppila Dan Salvail Charles-E. Laurent 4 1,2 5 1,2 • • • • Marie-Claude Benoit Simo Syrja ¨ la ¨ Heikki Helin Karl Lemstro ¨ m 6,7 Riitta Lassila Received: 2 May 2016 / Accepted: 6 July 2016 / Published online: 12 July 2016 Japanese Society of Nephrology 2016 Abstract or -UFH were monitored by PET/CT. Next, APAC and Background Renal ischemia–reperfusion predisposes to UFH doses (0.06 and 0.13 mg/kg) were i.v. administered acute kidney injury (AKI) and mortality. APAC, mast cell 10 min prior to renal ischemia–reperfusion injury (IRI) in heparin proteoglycan mimetic is a potent dual antiplatelet rats. and anticoagulant inhibiting thrombosis in several vascular Results APAC in contrast to UFH inhibited platelet models. aggregation. During 0.06 and 0.13 mg/kg dose regimens Methods Clinically relevant (0.06 and 0.13 mg/kg) and APTT and PT remained at baseline, but at the high APTT high (0.32 and 7.3 mg/kg) heparin doses of APAC and prolonged fourfold to sixfold. Overall bio-distribution and unfractionated 
TI - Dual antiplatelet and anticoagulant APAC prevents experimental ischemia–reperfusion-induced acute kidney injury
JF - Clinical and Experimental Nephrology
DO - 10.1007/s10157-016-1308-2
DA - 2016-07-12
UR - https://www.deepdyve.com/lp/springer-journals/dual-antiplatelet-and-anticoagulant-apac-prevents-experimental-PQHSrgV0p0
SP - 436
EP - 445
VL - 21
IS - 3
DP - DeepDyve
ER -